| Texto completo | |
| Autor(es): Mostrar menos - |
Caridha, Diana
;
Vesely, Brian
;
van Bocxlaer, Katrien
;
Arana, Byron
;
Mowbray, Charles E.
;
Rafati, Sima
;
Uliana, Silvia
;
Reguera, Rosa
;
Kreishman-Deitrick, Mara
;
Sciotti, Richard
;
Buffet, Pierre
;
Croft, Simon L.
Número total de Autores: 12
|
| Tipo de documento: | Artigo Científico |
| Fonte: | INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 11, p. 12-pg., 2019-12-01. |
| Resumo | |
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro and in vivo assays, models and approaches taken over the past decade to establish a pathway for the discovery, and pre-clinical development of new drugs for CL. These recent advances include novel mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches to skin infection, and defined pre-clinical candidate profiles. (AU) | |
| Processo FAPESP: | 15/09080-2 - Avaliação de candidatos a fármacos para o tratamento de leishmaniose no Brasil |
| Beneficiário: | Silvia Reni Bortolin Uliana |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |